References
- . Bolin K, Wilson K, Benhaddi H, . Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation—results from four European countries. Eur J Public Health. 2009;19(6):650–654
- . Annemans L, Nackaerts K, Bartsch P, Prignot J, Marbaix S. Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis. Clin Drug Investig. 2009;29(10):655–665
- . Reus VI, Obach RS, Coe JW, . Varenicline: new treatment with efficacy in smoking cessation. Drugs Today (Barc). 2007;43(2):65–75
- . Schnoll RA, Lerman C. Current and emerging pharmacotherapies for treating tobacco dependence. Expert Opin Emerg Drugs. 2006;11(3):429–444
- . Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2004;(3):CD000146
- . Cornuz J, Gilbert A, Pinget C, . Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care settings: a multinational comparison. Tob Control. 2006;15(3):152–159
- . Feenstra TL, Hamberg-van Reenen HH, Hoogenveen RT, Rutten-van Mölken MP. Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study. Value Health. 2005;8(3):178–190
- . Stapleton JA, Lowin A, Russell MA. Prescription of transdermal nicotine patches for smoking cessation in general practice: evaluation of cost-effectiveness. Lancet. 1999;354(9174):210–215
- . Wasley MA, McNagny SE, Phillips VL, Ahluwalia JS. The cost-effectiveness of the nicotine transdermal patch for smoking cessation. Prev Med. 1997;26(2):264–270
- . Woolacott NF, Jones L, Forbes CA, . The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation. Health Technol Assess. 2002;6(16):1–245
- . Linden K, Jormanainen V, Linna M, Sintonen H, Wilson K, Kotomäki T. Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers. Curr Med Res Opin. 2010;26(3):549–560
- . Knight C, Howard P, Baker CL, Marton JP. The cost-effectiveness of an extended course (12+12 weeks) of varenicline compared with other available smoking cessation strategies in the United States: an extension and update to the BENESCO model. Value Health. 2010;13(2):209–214
- . Bolin K, Mörk AC, Willers S, Lindgren B. Varenicline as compared to bupropion in smoking-cessation therapy—cost-utility results for Sweden 2003. Respir Med. 2008;102(5):699–710
- . Howard P, Knight C, Boler A, Baker C. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers. Pharmacoeconomics. 2008;26(6):497–511
- . Organization of American States. First National Study About Drug Consumption in the General Population of El Salvador. San Salvador, 2006
- . Bejarano J, Ugalde F. Drug consumption in Costa Rica. Results from the National Household Survey on Drug Abuse of 2000–2001. Institute on Alcoholism and Pharmacodependency; 2003
- . Cuadra JA; La Asociación Nicaragüense de Neumología. Tabaquismo en Nicaragua, http://www.neumoytorax.com/jc_tabaquismo_nicaragua.pdf. Accessed November 20, 2010
- . Hoogendoorn M, Welsing P, Rutten-van Mölken MP. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. Curr Med Res Opin. 2008;24(1):51–61
- . Sanitary Products and Spanish Medications Agency. Technical File, Nicorette transdermic patches. Ministry of Public Health, Social Politics and Equality, Madrid. [Agencia Española de Medicamentos y Productos Sanitarios. Ficha técnica. Parches transdérmicos de nicotina. Ministerio de Sanidad, Política Social e Igualdad, Madrid.]
- . National PBM Drug Monograph. Varenicline (Chantix$tM). http://www.pbm.va.gov/Clinical%20Guidance/Drug%20Monographs/Varenicline.pdf. December 2006. Accessed November 20, 2010
- . Index Mundi. Guatemala demographics profile 2012. http://www.indexmundi.com/guatemala/demographics_profile.html. Accessed November 20, 2010
- . Index Mundi. Nicaragua demographics profile 2012. http://www.indexmundi.com/nicaragua/demographics_profile.html. Accessed November 20, 2010
- . Index Mundi. Panama demographics profile 2012. http://www.indexmundi.com/panama/demographics_profile.html. Accessed November 10, 2010
- . Nutrinet. Situación de salud en las Américas: Indicadores básicos 2009. http://www.nutrinet.org/servicios/noticias/1/1267-situacion-de-salud-en-las-americas-indicadores-basicos-2009. Published October 26, 2009. Accessed November 20, 2010
- . Lutz-Ramírez M, Heibron E. Cost-effectiveness of varenicline versus all interventions for quitting smoking cessation in the adult population of Costa Rica using the BENESCO model. Acta Méd Costarric. 2010;52(4). http://www.scielo.sa.cr/scielo.php?pid=S0001-60022010000400006&script=sc_arttext. Accessed January 23, 2011
- . National Institute of Public Health. Council of General Health Regulations. General Management of Prioritization. Interinstitutional Committee of the Basic Resources of the Health Sector. Guide for the development of economic evaluation studies for the update of the Basic Resources of the Health Sector in Mexico, http://www.csg.salud.gob.mx/descargas/pdfs/cuadro_basico/GUxA_EVAL_ECON25082008_2_ech.pdf. August 2008. Accessed May 23, 2011
- . McDowell I, Mothersill K, Rosser W, Hartman R. A randomized trial of three approaches to smoking cessation. Can Fam Physician. 1985;31:845–851
- . Spencer M, Briggs AH, Grossman RF, Rance L. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics. 2005;23(6):619–637
- . Mannino DM, Buist AS, Petty TL, Enright PL, Redd SC. Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax. 2003;58(5):388–393
- . Trippoli S, Vaiani M, Lucioni C, Messori A. Quality of life and utility in patients with non-small cell lung cancer. Quality-of-life Study Group of the Master 2 Project in Pharmacoeconomics. Pharmacoeconomics. 2001;19(8):855–863
- . Hay JW, Sterling KL. Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease. Pharmacoeconomics. 2005;23(2):133–141
- . Fryback DG, Dasbach EJ, Klein R, . The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making. 1993;13(2):89–102
- . Tengs TO, Lin TH. A meta-analysis of quality-of-life estimates for stroke. Pharmacoeconomics. 2003;21(3):191–200
- . Duncan PW, Lai SM, Keighley J. Defining post-stroke recovery: implications for design and interpretation of drug trials. Neuropharmacology. 2000;39(5):835–841
- . World Health Organization. CHOosing Interventions that are Cost Effective (WHO-CHOICE). Table: threshold values for intervention cost-effectiveness by region. http://www.who.int/choice/costs/CER_levels/en/index.html. Accessed November 20, 2010
- . Index Mundi. Nicaragua GDP—per capita (PPP) http://www.mdex-mundi.com/nicaragua/gdp_per_capita_%28ppp%29.html. Accessed November 20, 2010
- . Index Mundi. Panama GDP—per capita (PPP) http://www.indexmundi.com/panama/gdp_per_capita_%28ppp%29.html. Accessed November 20, 2010
- . Index Mundi. Costa Rica GDP—per capita (PPP) http://www.mdex-mundi.com/costa_rica/gdp_per_capita_%28ppp%29.html. Accessed November 20, 2010